Regen BioPharma develops new ways to use CAR-T cell immunotherapy to attack solid tumors

The company is developing a two-step sequential approach

SAN DIEGO, August 25, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) today announced the development of a novel immunotherapy for the treatment of solid tumors. Current cellular approaches to killing cancer involve administering a specific type of engineered T cells called “chimeric antigen receptor” (CAR) T cells. Despite significant advances in the use of CAR-T cells to treat leukemia, little progress has been made in solid tumors such as those found in the lungs, brain, breast, prostate and colon. Solid tumors are thought to possess an abnormal “microenvironment” that physically prevents T cells from entering the tumor, as well as inactivating T cells that do manage to enter. The microenvironment consists of surrounding blood vessels, immune cells, fibroblasts, signaling molecules, and an extracellular matrix. The solid tumor is surrounded by its microenvironment and constantly interacts with it.

The current approach developed by the Company, for which a provisional patent application has been filed, consists of an initial treatment of the tumor microenvironment with cells of the innate immune system called CAR-M and CAR-NK cells. These cells, which also begin to attack the tumor, are able to “normalize” the tumor microenvironment, allowing CAR-T cells to enter and attack the tumor.

“The company believes that taking this two-step approach – first softening the target with CAR-M and CAR-NK cells, then bringing in the heavy artillery (CAR-T cells) will allow solid tumors to be successfully targeted by these cell therapies, thereby greatly expanding the CAR-T market and ultimately saving lives,” said Dr. David KoosCEO and President of the Company.

About Regen BioPharma Inc.:

Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the field of immunology and immunotherapy. The company is focused on rapidly advancing new technologies through preclinical and Phase I/II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for the treatment of cancer and autoimmune diseases. Additional information about Regen BioPharma is available at http://www.regenbiopharmainc.com.

Disclaimer: This announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those stated, contemplated or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

CONTACT INFORMATION

Regen BioPharma Inc.
David R. Koosdoctorate
CEO
+1-619-722-5505 Telephone
+1-619-330-2328 Fax
http://www.regenbiopharma.com
[email protected]

Follow us on Twitter for future updates: https://twitter.com/TheRegenBio

SOURCERegen BioPharma, Inc.

Irene B. Bowles